Over the past five decades, a plethora of nonrandom chromosomal abnormalities have been consistently reported in malignant cells facilitating the identification of cancer-associated protein coding oncogenes and tumor suppressors. The genetic dissection of hot spots for chromosomal abnormalities in the age of the sequenced human genome resulted in the discovery that microRNA (miRNA) genes, encoding for a class of small noncoding RNAs, frequently resides in such genomic regions. The combination of nonrandom chromosomal abnormalities and other types of genetic alterations or epigenetic events contribute to downregulation or overexpression of miRNAs. The consequent abnormal expression of miRNAs affect cell cycle, survival and differentiation programs and selective targeting of these noncoding genes could provide novel therapeutic options for killing the malignant cells. Oncogene (2006 Oncogene ( ) 25, 6202-6210. doi:10.1038 Keywords: microRNAs; chromosomal aberrations; cancer
For several chromosomal abnormalities no culprit protein coding gene(s) was identified
Over the past five decades, a plethora of nonrandom chromosomal abnormalities have been consistently reported in malignant cells of hematopoietic and solid tumors (Nowell and Hungerford, 1960; Rowley, 1973; Croce and Nowell, 1985) facilitating the identification of cancer-associated protein coding oncogenes (OGs) and tumor suppressor gene(s) (TSG(s)) (Russo et al., 1988; Bishop, 1991; Rabbits, 2001) . Numerical and structural chromosomal aberrations have been systematically reported in the Mitelman Database of Chromosome Aberrations in Cancer (for more information, see http:// cgap.nci.nih.gov/Chromosomes/Mittelman). The database passed the mark of 50 000 cases in the July update, and reports for new abnormalities are accumulating at high rate with the advance of cytogenetics techniques such as spectral karyotype analysis. One classical paradigm is represented by the c-Myc myelocytomatosis viral (avian) oncogene homolog activation in Burkitt's lymphoma (BL): about 80% of cases harbor the t(8:14) that juxtaposes c-Myc on chromosome 8 with IgH enhancer elements on chromosome 14 with consequent mRNA and protein overproduction (Dalla-Favera et al., 1982) . In the remaining 20% of cases, the same effects are achieved by t(2;8) and t(8;22), placing c-Myc adjacent to either kappa or lambda light chain loci and enhancer elements (Croce et al., 1983) . As MYC protein is a helix-loop-helix leucine zipper transcription factor, consequently to its overexpression, the levels of several dozens of genes involved in the cell cycle regulation, apoptosis, and differentiation of germinal center B cells are altered (reviewed in Sanchez-Beato et al. (2003) ).
Furthermore, the genomes of cancer cells contain abnormalities undetectable by any type of cytogenetic investigation such as deletions and amplifications, sometimes in the range of several tens of kilobases, defined experimentally by minimal regions of loss of heterozygosity (LOH), and minimal amplicons. In spite of careful genomic dissection, some chromosomal abnormalities had unknown targets and the mechanisms by which these changes affect certain specific disorders remained unraveled for long time. For example, overexpression of BCL2 protein was reported in many types of human cancers including leukemias, lymphomas and carcinomas (Sanchez-Beato et al., 2003) . In follicular lymphomas and in a fraction of diffuse B-cell lymphomas, the mechanism of B-cell leukemia/lymphoma 2 gene (Bcl-2) activation was found to be the translocation t(14;18) (q32;q21), which places Bcl-2 gene under the control of immunoglobulin heavy chain enhancers, resulting in deregulated expression of the gene (Tsujimoto et al., 1984 (Tsujimoto et al., , 1985 . In the most frequent adult leukemia in the Western world, the B-cell chronic lymphocytic leukemia (CLL) (Chiorazzi et al., 2005) , the malignant, mostly nondividing, B cells of CLL overexpress BCL2 protein (Kitada et al., 1998) . However, with the exception of less than 5% of cases in which Bcl-2 is juxtaposed to immunoglobulin loci (Adachi et al., 1990) , no mechanism was discovered to explain BCL2 deregulation in CLL.
The answer to this unsolved puzzle came from a decade long study of the most frequent deleted genomic region in CLL at chromosomal band 13q14.3, that is easily detected by cytogenetics and is associated with the longest treatment-free interval (Dohner et al., 2000) . Hemizygous and/or homozygous loss at 13q14.3 occur in more than half of cases and constitute the most frequent chromosomal abnormality in CLL (Bullrich et al., 2001) . 13q14.3 deletions also occur in B50% of mantle cell lymphoma, in up to 40% of multiple myeloma, and in 60% of prostate cancers (Dong et al., 2001) , suggesting that one or more TSG(s) at 13q14.3 may be involved in the pathogenesis of these human tumors. CLL have relatively few consistent chromosomal abnormalities, suggesting that because of the specificity and frequency of observed deletions at 13q14.3 they are of pathologic significance. Several groups have used positional cloning to identify the gene or genes targeted by the deletions. A region of more than 1 Mb has been fully sequenced and characterized in detail (Bullrich et al., 2001) . One of the difficulties first encountered during analysis of this locus was the lack of a clear definition of the minimal region of loss. In fact, various and relatively large (between 130 and 550 kb) minimal regions of LOH at 13q14.3 have been described in CLL (Figure 1 ). Until year 2001, a total of eleven genes have been identified and screened for alterations at the DNA and/or RNA level in sporadic and familial cases of CLL. However, detailed genetic analysis, including extensive LOH, mutation and expression studies, failed to demonstrate the consistent involvement of any of the genes located in the deleted region (described in Calin et al. (2005c) and Migliazza et al. (2001) ).
In order to decipher the nature of elusive TSG(s) at 13q14.3, in 2001 we generated somatic cell hybrids between mouse LMTK-(thymidine kinase deficient) and human CLL cells carrying 13q14.3 translocations and/ or deletions and, using these hybrids, we identified a 30-kb region of deletion between exons 2 and 5 of LEU2 gene (Calin et al., 2002) . The same region was involved in translocations observed in CLL patients (Calin et al., 2002) . We continued to search for genes within the region using publicly available sequence information and databases. This resulted in the discovery that a cluster of two noncoding microRNA (miRNA) genes, miR-15a and miR-16-1, is located precisely in the deleted region and is involved in the analysed translocation ( Figure 1 ) (Calin et al., 2002) . Further detailed investigation showed that both genes are deleted or downregulated in approximately 68% of CLL cases as compared with CD5 þ lymphocytes from healthy donors (Calin et al., 2002) . Furthermore, a rare mutation identified in two CLL patients including one from a family with individuals having CLL and breast cancer, and possibly affecting the expression of these genes was found to be associated with the loss of the normal allele in the leukemic cells (Calin et al., 2005a) . Fully explaining the tumor-suppressor function of miR-15 and miR-16, it was proved that the levels of both genes inversely correlates with the BCL2 protein expression, and that BCL2 repression by miR-15a and miR-16-1 induces apoptopsis in leukemia cells (Cimmino et al., 2005) .
miRNAs are located at cancer-associated genomic regions
The genetic dissection of hot spots for chromosomal abnormalities in the age of the sequenced human genome showed that miRNAs, a small noncoding RNA class of genes, frequently resides in such genomic regions (Calin et al., 2004b) . Ambros group (Lee et al., 1993) first described miRNAs in 1993 in Caenorhabditis elegans. At present days, over 3500 members of this new class of small noncoding RNAs (ncRNAs), have been identified in the last four years in vertebrates, flies, worms and plants, and also in viruses (Ambros, 2003; Bartel, 2004; Griffiths-Jones et al., 2006) . The miRNA functions are ubiquitous, raging from the control of leaf and flower development in plants to the modulation of hematopoietic lineage differentiation in mammals (Chen et al., 2004) . Several groups have uncovered roles for miRNAs in the coordination of cell proliferation and cell death during development, and in stress resistance and fat metabolism (for reviews see Ambros (2003); Figure 1 The 13q14.3 deletions in CLL cells target the miR15a/ miR-16-1 cluster. The upper panel shows several minimal regions of deletion, the one identified by cell hybrids experiments and containing the cluster of miR-15a/miR-16-1 being right-dashed. The genomic markers as well as the gene orientation are indicated. The lower panel shows the genes located inside or very close to the deleted region (the gene symbols are as in NCBI at http:// www.ncbi.nlm.nih.gov/entrez). Of note, all the genes are located in the centromeric half of the analysed genomic region, while no gene in the large genomic desert of the telomeric 750 kb was found. This region is rich in noncoding RNAs (ncRNAs) because four RNAs without correspondent protein have been found. DLEU1 and DLEU2 are members of the large ncRNAs subfamily (with transcripts of about 0.6-6 and 14-18 kb, respectively), while miR-15a/miR-16-1 are members of the small ncRNAs subfamily of miRNAs (with precursors of about 70 nc). The genes in blue are protein coding, while the red ones are noncoding, meaning coding for RNAs without an open reading frame (ORF). For the identification of the minimal region of deletion, somatic cell hybrids were generated following conventional methods and selected in hypoxanthine-aminopterin-thymidine. We generated 15 fusion clones isolated from fusion of a CLL case (CLL-B) carrying a t(2;13) (q32; q14) translocation and one clone was isolated from fusion of another CLL case (CLL-A) carrying a t(2;13) (q12; q13) translocation. Twelve CLL-B derived clones carried a full complement of both chromosomes 13 and 2, whereas three carried the derivative chromosome 13 and a full complement of chromosome 2. The single clone from CLL-A carried a chromosome 13 with a small deletion at 13q14. Bartel (2004) and Harfe (2005) ). Functionally, it was shown that miRNAs reduce the levels of many of their target transcripts as well as the amount of protein encoded by these transcripts (Lim et al., 2005) .
In order to check if the genetic association between miR-15a and miR-16-1 with a nonrandom cytogenetic abnormality occurring in a region that frequently contains a homozygous deletion (HD) is simply by chance, we decided to investigate at a genome-wide level the association between various cytogenetic and molecular abnormalities and the location of miRNA genes. As in 2003 few human miRNA genes were reported, we initiated the bioinformatics study by cloning 'in silico' all the human homologous miRNAs corresponding to the genes discovered at that time in various species (mainly mouse, Drosophila and Caenorhabditis) and obtained a database of 186 human miRNAs. As the second step, we generated several databases containing the exact genomic positions of markers used for cloning cancer-associated genomic regions (CAGR), including 157 minimal regions of loss-of-heterozygosity (LOH), suggestive of the presence of TSG(s), 37 minimal regions of amplification, suggestive of the presence of OG(s), 45 common breakpoint regions in or near possible OG(s) or TSG(s) and 29 fragile sites (FRA). A substantial body of evidence supports the proposal that at least some common chromosomal FRA predispose to DNA instability in cancer cells (Richards, 2001; Arlt et al., 2003) . Indeed, FRA are preferential sites of sister chromatid exchange, translocation, deletion, amplification or integration of plasmid DNA and tumorassociated viruses such as human papilloma virus (HPV). The results were surprising and suggested a larger than thought involvement of miRNAs in cancer. Overall, we found that more than half of miRNA genes were located in CAGRs, including 65 miRNAs located exactly in minimal regions of LOH, and 15 miRNAs in minimal regions of amplification, described in a variety of tumors, including lung, breast, ovarian, colon, gastric and hepatocellular carcinoma as well as leukemias and lymphomas. In addition, looking at 113 FRA scattered in human karyotype, we found that 61 miRNAs are located in the same cytogenetic positions with FRA ( Figure 2) (Calin et al., 2004b) .
The first report linking a chromosomal breakpoint with the genomic location of miRNAs was done by Croce group a couple of decades ago (Gauwerky et al., 1989) . By analyzing the oncogene rearrangements involving c-Myc in leukemia cells, a masked t(8;17) translocation that resulted in a high activation of the oncogene was identified. The sequence analysis revealed that c-Myc from chromosome 8 was truncated at the end of first exon (which is noncoding) and the coding region joined the regulatory elements of a gene located on chromosome 17, called BCL3 (B-cell leukemia/ lymphoma 3) and transcribed as a 1.7 kb message in a variety of hematopoietic cell lines. In spite of extensive genomic search, BCL3 remained an elusive entity until the identification of the human miRNAs. After 15 years from the initial discovery, it was found that miR-142 gene is located 50 nt from the t(8;17) break involving chromosome 17 and c-Myc, meaning that the regulatory elements of this miRNA are likely involved in the overexpression of MYC (Calin et al., 2004b) . The clinical consequences were dramatic for the patient, leading to an aggressive acute prolymphocytic leukemia that presumably derived from precursors of an indolent lymphoma carrying a rearranged Bcl-2 gene (Gauwerky et al., 1989) . Apart from the involvement in the t(8;17) breakpoint in acute leukemia, miR-142-3p and miR-142-5p are also within the 17q23 minimal amplicon described in breast cancer (Barlund et al., 2000) and near the FRA17B site, a target for HPV16 integration in cervical tumors (Calin et al., 2004b) .
Other examples of miRNA genes located near breakpoint regions include miR-180 at 1 kb from the MN1 gene (meningioma (disrupted in balanced translocation) 1) involved in a t(4;22) in meningioma that inactivates MN1 gene and possibly the miRNA gene located in the same position. Also, in a patient with precursor B-cell acute lymphoblastic leukemia an insertion of miR-125b-1 into a rearranged immunoglobulin heavy chain locus was described, possibly an early step in leukemogesis (Sonoki et al., 2005) . Arguing for the importance of miRNA aberrations by chromosomal rearrangements, come the identification of a similar mechanism in the development of a tumor of another species, the woodchuck hepatocellular carcinoma. Sequence comparisons showed the woodchuck homolog of human miR-122a is in sense orientation with the ORF of hcr gene from woodchuck, a noncoding gene involved in a rearrangement with c-Myc in a woodchuck hepatocellular carcinoma (Etiemble et al., 1989) . Further supporting the suggested role of miR-122a in cancer, we found that the human miR-122a is located in the minimal amplicon around MALT1 in aggressive marginal zone lymphoma (MZL) and about 160 kb from the breakpoint region of translocation t(11;18) in mucosaassociated lymphoid tissue (MALT) lymphoma (Calin et al., 2004b) .
Various regions frequently altered in cancer, but without clear culprit genes, were shown to contain clusters of miRNAs. For example, in breast carcinomas two different regions of loss at 11q23, independent from ataxia telangiectasia-mutated (ATM) locus have been studied extensively: the first spans about 2 Mb between loci D11S1347-D11S927, the second is located between loci D11S1345-D11S1316 and is estimated at about 1Mb (di Iasio et al., 1999) . Candidate TSG(s) were not found in spite of extensive effort, except the PPP2R1B (protein phosphatase 2, regulatory subunit A, beta isoform) gene, involved in o10% of cases (Wang et al., 1998; Calin et al., 2002) . Both minimal LOH regions contain numerous miRNAs: the cluster miR-34b/ miR-34c in the first and the cluster miR-125b-1/let-7a-2/ miR-100 in the second. High frequency of LOH at 17p13.3 and relatively low frequency of TP53 mutation in cases of hepatocellular carcinomas (HCC), lung cancers and astrocytomas indicate the presence of other TSGs involved in the development of these tumors. We have found that one minimal LOH region described in HCC and located telomeric to TP53 (tumor protein p53) gene between markers D17S1866 and D17S1574 (Zhao et al., 2003) harbor three miRNAs: miR-22, miR-132 and miR-212, while between ENO3 and TP53 (Tsuchiya et al., 2000) we found miR-195 (Calin et al., 2004b) .
Homozygous deletions in cancer suggest the presence of TSGs (Huebner et al., 1998) and several miRNA genes are located in homozygously deleted regions without known culprit. In addition to miR-15a and miR-16a located at 13q14.3 HD region in B-CLL, the cluster miR-99a/let-7c/miR-125b-2 mapped in a 21p11.1 region of HD in lung cancers and miR-32 at 9q31.2 in a region of HD in various types of cancer. Among the seven regions of LOH and HD on the short arm of chromosome 3 three of them harbor miRNAs: miR-26a in region AP20, miR-138-1 in region 5 at 3p21.3 and the cluster let-7g/miR-135-1 in region 3 at 3p21.1-p21.2 (Zabarovsky et al., 2002) . All these data taken together strongly support the fact that the association between miRNAs and chromosomal abnormalities in cancer cells is not casual, leading to the possibility that more examples will be identified in the near future.
Chromosomal abnormalities as a cause of disturbed miRNAs expression
Several arguments suggest that the highly significant association between the location of miRNAs and chromosomal or molecular genomic aberrations is not without consequences. First, this association is specific for the miRNA class of genes, as is not true for several other classes of genes (e.g., the RNA splicing family of genes) (Table 1) . Second, considering the additional several hundreds of cloned miRNAs carefully recorded at miRBase (http://microrna.sanger.ac.uk/cgi-bin/ sequences/) (Griffiths-Jones et al., 2006) or predicted miRNAs as extensively published in the last years Xie et al., 2005) , the association remain highly significant. The meaning of this finding is that this is not a peculiarity of the first set of cloned miRNAs, that are also the most extensively and highly expressed in human cells (GAC, JP Hagan and CMC, unpublished data). Third, it was shown by Northern blottings, that the genomic location influence the miRNA expression: miR-16a expression (located at 13q14.3) was low or absent in the majority of B-CLL cases while the expression of miR-26a (at 3p21) and miR-99a (at 21q11.2), both regions not involved in B-CLL, was at relatively equal levels in all cases. By contrast, both miR-26a and miR-99a are not expressed or are expressed at low levels in lung cancer cell lines, and this correlate with their location in regions of LOH/ HD in lung tumors/cell lines. On the other hand, the expression of miR-16a was the same in the majority of cell lines as in normal lung (Calin et al., 2004b) . Fourth, an extensive study of high-resolution array-based comparative genomic hybridization on 227 human ovarian cancer, breast cancer and melanoma specimens, clearly proved that regions hosting miRNAs exhibit high-frequency genomic alterations in human cancer. Strengthening the importance of these findings is the fact that miRNA copy changes correlate with miRNA expression (Zhang et al., 2006) . The analyses of the same histotype, breast ductal carcinomas, performed by two independent groups using distinct techniques, revealed overlapping sets of miRNAs that are differentially expressed and miRNAs that are located in genomic regions with DNA copy number gains or losses (Zhang et al., 2006) compared to normal breast tissues. As shown in Table 2 , the majority of miRNAs causally linked to human tumorigenesis are located in genomic regions altered in cancer and the genomic abnormality is concordant with the expression deregulation (genomic deletion for downregulation and amplification for upregulation, respectively).
If the location of miRNAs is relevant to tumorigenesis, then structural or functional alterations of miRNAs should be identified in various types of cancers. A growing number of reports are providing such evidence and suggest that abnormal expression of miRNAs is central to cancer pathogeny (reviewed in McManus (2003) (2006); Hwang and Mendell (2006) and Calin and Croce (2006b) ). The combination of nonrandom chromosomal abnormalities and other types of genetic or epigenetic events could contribute to downregulation or overexpression of miRNAs (Figure 3 ). The dimensions of miRNAs are quite small in respect with the cDNAs of protein coding genes, and therefore the mutations in miRNA transcripts should be rare events. A combination of LOH þ mutation was reported as inactivating 'two-hit' events in two cases of CLL (Calin et al., 2005a) , while a naturally occurring sequence polymorphism in an miRNA precursor that results in reduced processing and lower levels of mature miRNA expression and function has been reported (Gottwein et al., 2006 ). An independent study on human cancer cell lines showed that heterozygous genetic variants in miRNA precursors are common, but are unlikely to have physiologic significance (Diederichs and Haber, 2006) . Further expanding the ways in which miRNA expression could be altered, it was proved that DNA demethylation and histone deacetylase inhibition can activate expression of miR-127 that may act as a tumor suppressor by targeting the BCL6 (B-cell leukemia/lymphoma 6) proto-oncogene (Saito et al., 2006) .
Up to date, two large profiling studies using tumors of various histotypes were published Volinia et al., 2006) . Lu et al. (2005) using a bead-based flow-cytometric profiling technology performed on a set of 334 including multiple human cancers mainly leukemias, found that miRNA expression profiles classify human cancers reflecting the developmental lineage and differentiation state of the tumors. Of important diagnostic consequences, the miRNA-based classifier is far better in establishing the correct diagnosis of poorly differentiated samples than the protein coding genes messenger RNA classifier (Po5 Â 10 -11 vs P ¼ 0.47). Volinia et al. (2006) described a detailed analysis by microarray in 540 samples from six solid types of the most frequent human cancers and found a common signature composed by 61 miRNAs, mainly overexpressed in respect with correspondent normal tissues. Supporting the roles of these genes in tumorigenesis, it was found that the predicted targets for the differentially expressed miRNAs are significantly enriched for protein-coding TSG(s) and OG(s) (Po0.0001). To test hypotheses related to the incidence of miRNAs and RNA splicing genes and association with FRA, amplified regions in cancer, and deleted regions in cancer, we utilized random effect Poisson regression models as described in Calin et al. (2004b) .
b Too few events, likelihood-based models are numerically unstable. Bold represents statistically significant P-values. After the identification of specific miRNA signatures in CLL (Calin et al., 2004a (Calin et al., , 2005a , miRNAs differentially expressed between tumors and normal counterparts were identified for several tumor types like lymphoma (He et al., 2005b) , breast cancer , lung cancer (Yanaihara et al., 2006) , thyroid papillary carcinoma (He et al., 2005a) , glioblastoma (Ciafre et al., 2005) , hepatocellular carcinoma (Murakami et al., 2006) , colorectal carcinoma (Cummins et al., 2006) and pancreatic tumors (Roldo et al., 2006) .
It is logical to question why this association between CAGR and miRNAs is of significant pathogenetic importance for tumorigenesis. The answer could be that genomic aberrations in primary tumors preferentially involve the genomic loci where miRNA resides (Calin et al., 2004b; Zhang et al., 2006) . The consequence is that the clones having genomic aberrations involving miRNA loci have biological advantages consequent to disturbed miRNAs expression.
Abnormal miRNAs expression in cancer can be therapeutically exploited
If the abnormalities of genomic loci containing miRNAs are causal for human cancer, then the abnormal expression of these genes should affect fundamental cell programs, such as cell cycle and survival or differentiation programs. A growing list of examples of causeeffect relations explaining the intimate involvement of miRNA in cancer is now available (Table 2) . Therefore, miRNAs might be potential targets for therapy, as knocking down overexpressed miRNAs or expressing silenced miRNAs in cancer cells might contribute to tumor killing. While the pathogenetic mechanisms and the therapeutic consequences of deregulation of various miRNAs (such as let-7 family, the cluster miR-17-5p/ miR-92 or the cluster miR-15a/miR-16-1) were subject to extensive reviews (see Morris and McManus (2005) ; Czech (2006) ; Slack and Weidhans (2006) and Calin and Croce (2006a, b) , we will briefly focus only on two very recent findings.
The list of oncogenic miRNAs includes miR-21, the cluster miR-17-5p-miR-92, miR-155 and the cluster miR-372/miR-373 (Table 2) . MiR-21 is located in 3 0 UTR of VMP1 (vacuole membrane protein 1) gene at chromosome 17q23.2, a region amplified in neuroblastomas and in breast, colon and lung cancers. Consequently, miR-21 was found as the only miRNA overexpressed in all six types of solid cancers (breast, colon, lung, prostate and stomach carcinomas and pancreas exocrine tumors) analysed in the study by Volinia et al. (2006) , as well as in glioblastomas (Chan et al., 2005; Ciafre et al., 2005) . Knockdown of miR-21 in cultured glioblastoma cells triggers apoptosis by a caspase-dependent mechanism Figure 3 Consequences of the cooperation between chromosomal and molecular alterations affecting miRNA loci in human cancers. Some of the well-characterized molecular models for miRNA involvement in cancers are presented. The effects of deletions (del), mutations (mut), promoter hypermethylation (hypermethyl), amplification (amplif) or translocations (t) are presented. The diagrams are simplified and did not account for all the molecular complexity, as combinatorial effects of multiple miRNAs acting on the same target or multiple targets influenced by the same miRNA were proposed. Furthermore, only the main functional consequences were presented. The promoter regions are presented as orange triangles and the structural miRNA genes as blue circles. C-Myc gene is presented as a blue rectangle. (Chan et al., 2005) . Studies in cholangiocarcinoma cells proved that one direct target of miR-21 is the TSG gene PTEN (phosphatase and tensin homolog (mutated in multiple advanced cancers 1)), that encodes a phosphatase that normally inhibits the survival/ growth promoting activity of phosphoinositole 3-kinase (PI-3 kinase) signaling (Cully et al., 2006) . It was proved that miR-21 modulates gemcitabine-induced apoptosis by PTEN-dependent activation of PI 3-kinase and activation of AKT/mTOR signaling (Meng et al., 2006) . Together these two findings suggest that miR-21 is an antiapoptotic and prosurvival factor and therefore, the therapeutically potential is obvious: inhibition of this miRNA should result in cell death. As both cholangiocarcinomas and glioblastomas are highly aggressive tumors with a very bad prognosis, identification of potential new therapeutic agents is of high priority.
The list of tumor-suppressors miRNAs includes the cluster miR-15a/miR-16-1, the cluster miR-145/miR-143, let-7 family and miR-127. MiR-127 is located on chromosome 14q32.31, in a region involved in several types of translocations identified in hematological cancers and deleted by LOH in solid cancers. Consequently, its expression is reduced or absent in various types of cancers (Saito et al., 2006) . While the treatment of cancer cells with the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5-Aza-CdR) has a small influence on miRNA expression, the combined treatment 5-Aza-CdR and the histone deacetylase (HDAC) inhibitor 4-phenylbutyric acid (PBA) has significant effects. The most differentially expressed miRNA after the combined 5-Aza-CdR þ PBA administration in human bladder cancer cells was miR-127. Further investigations showed that miR-127 can downregulate the oncogene BCL6 by translational repression (Saito et al., 2006) . BCL6 is a zinc-finger transcription repressor that modulates DNA damage-induced apoptosis in germinal center B cells (Phan and DallaFavera, 2004) . Therefore, induction of miR-127 by 5-Aza-CdR and PBA treatment in cancer cells might have an anticancer effect by downregulation of antiapoptotic factors such as BCL6 and consequent apoptosis.
Concluding remarks
Loss or amplification of miRNA genes by gross cytogenetic abnormalities or minute molecular aberrations has been observed in a variety of human malignancies and more than half of the miRNoma was proved to be located in such regions. Several genomic regions in which the hunting for culprits failed, have been shown to harbor clusters of miRNA genes. The consequence of such aberrations is altered expression of these small noncoding regulatory genes that influence the levels of various protein coding genes that are key players in the survival, proliferation and differentiation programs of both hematopoietic and solid tissue cells. Thus, miRNAs might be potential targets for therapy, as knocking down overexpressed miRNAs or expressing silenced miRNAs in cancer cells might contribute to tumor killing.
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